📢Our lab at the @CarrerasIJC is looking for candidates for the competitive PhD INPhINIT incoming fellowship from La Caixa Foundation. We work on the application of #singlecell genomics and ML to improve cell-based immunotherapy in Myeloma and others B-cell neoplasms. Plz RT!🔁
Ever wondered why we do all these #Omics?
Here is your answer: https://t.co/wexzIPc5wt 📜
Multi-Omics integration of a Human Cell Atlas (@humancellatlas ) of the Kidney, coordinated by the #HCA Standards and Technology Working Group and co-led by @eli_mereu.
Datasets:
10x Genomics scRNA 3´and 5 plus single-nuclei 3´ RNA-seq. Special guests: Smart-seq2 and scNMT-seq.
Highlights:
1. Identification of rare and clinically relevant cell types, such as WFDC2+ thick ascending limb cells and Norn cells (EPO-producing fibroblasts).
2. Improved kidney disease trait heritability analysis and enhanced functional annotation of disease-associated loci.
Extra feature:
scOMM, an interpretable machine learning tool for multimodal cell-type classification and benchmarking.
Enjoy reading bioRxiv & medRxiv:
https://t.co/wexzIPc5wt
Happy to share our new preprint: A spatial transcriptomics atlas of live donors reveals unique zonation patterns in the healthy human liver: https://t.co/r3YPO8YnaI
🔥New Fraticelli lab publication🔥
“Pre-existing stem cell heterogeneity dictates clonal responses to the acquisition of leukemia driver mutations”
Two new figures compared to the pre-print, with more in vivo and sequential mutagenesis data.
https://t.co/2MByy2tcO0
Today, 2⃣ postdoctoral researchers from @CarrerasLeaders have led our Young Researcher Seminars 🙌
🧑🔬👩🔬 Gerard Martínez (@sergicuartero lab) has presented his work on myeloid leukemia of Down syndrome and Alessia Buratin (@eli_mereu lab) has talked about machine learning to enhance CAR-T therapies
How does multiple myeloma progress? In our latest @SciImmunology cover story, we reveal how myeloma cells breaking through bone trigger dangerous diversity. This arises from bidirectional interactions with the immune system, fueling disease evolution. https://t.co/5tkvRYfxVv 1/2
Bye bye, bispecific? Check out our commentary on the development of a CD19/BCMA dual targeting CAR-T for non-Hodgkin Lymphoma led by Bachiller et al.
@GuedanS@MolTherapy
Co-transduction for the win! Link below ⬇️ for free access https://t.co/8f5q92fXs0…
@drclaireroddie
1/7 Planning to build a single-cell atlas? Or wondering how atlases can be useful to your research? Read our guide on single-cell atlases https://t.co/Z5dY86ZjxR published today in Nature Methods, by @SikkemaLisa, @KHrovatin, @MDLuecken, @fabian_theis and others.
💣Thrilled to announce that my first last-author publication is out! We investigated the presence of nuclei-free cells in 6 reference cell atlases (>20 tissues, >150 cell types) calculating the fraction of intronic reads and the expression of #MALAT1 in each cell🧵
How to write a grant?
1. Write it for the reviewer, not you, the applicant.
2. Communicate in stories.
3. Make your story cohesive—leave no puzzling gaps.
4. Make your story resonate to keep the reviewer reading.
5. Accept chance and noise in peer-review.
https://t.co/wHZ065DNlm
Tons of promising work using CAR T cells beyond cancer. Already showing signs of efficacy in early clinical reports. Check out our review in @Nature of this rapidly evolving field!
W/ @AranyLab@BaurLab @jonepstein1 @carlhjune
https://t.co/QlDYO8nWvK
Our latest work is out in @MolTherapy! We present ARI0003, dual-targeting CD19/BCMA CAR-T cells for lymphoma. We performed an exhaustive characterization of strategies to generate dual CAR-T cells. This CAR-T therapy is now under clinical investigation.
➡️ https://t.co/yMhjCAjyaq
Apply for Sanger Prize: Opportunity of doing a three-month internship at Wellcome Sanger Institute for undergraduate students from low or middle income country. Travel, living and research expenses are all covered by the award.
https://t.co/kf17LLHaNB